JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer modelsJAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models, Published online: 09 January 2019; doi:10.1038/s41417-018-0074-6JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

This study retrospectively investigated whether any patient characteristics, including ILA, were risk factors for ICI-ILD in patients with NSCLC.MethodsNSCLC patients who received anti-programmed death (PD)-1 antibody treatment at our hospital between September 2015 and December 2017 were enrolled. Information on patient characteristics before anti-PD-1 antibody administration, including chest CT findings and laboratory data, were obtained.ResultsAmong 83 enrolled patients, the incidence of ICI-ILD was 16.9% (14/83). All ICI-ILD cases developed by the third line of treatment. The incidence of ICI-ILD was significantly high...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Abstract BACKGROUND: Rural populations of the United States have not experienced a similar degree of decline in lung cancer mortality recently seen nationwide. Several investigations examining survival differences in rural lung cancer patients have been incongruent. We investigated the association of rural residence with survival outcomes and receipt of guidelines-concordant treatment in early-stage non-small cell lung cancer (NSCLC). METHODS: Retrospective study of National Cancer Data Base patients with NSCLC diagnosed from 2004 to 2015. Comparisons of survival outcomes and guidelines-concordant management ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Oncol Source Type: research
Conditions:   Video Assisted Thoracic Surgery (VATS);   Non-Small Cell Lung Cancer (NSCLC) Intervention:   Procedure: uniportal lobectomy with complete lymphadenectomy Sponsor:   Pulmonary Hospital Zakopane Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model. Oncol Rep. 2019 Jun 20;: Authors: Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L Abstract Human non‑small cell lung cancer (NSCLC) is associated with an extremely poor prognosis especially for the 40% of patients who develop brain metastasis, and few treatment strategies exist. Cucurbitacin E (CuE), an oxygenated tetracyclic triterpenoid isolated from plants particularly of the family Cucurbitaceae, has sh...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In this study, it was found that let‑7 family expression was downregulated and miR‑17 family expression was upregulated in gefitinib‑resistant PC9/GR cells compared with gefitinib‑sensitive PC9 cells. The downregulation of let‑7 and upregulation of miR‑17 have significant clinical relevance to gefitinib resistance in NSCLC. Moreover, it was shown that downregulation of let‑7 and upregulation of miR‑17 promoted resistance to gefitinib by regulating the self‑renewal capability of NSCLC cells. In addition, let‑7 participated in the maintenance of stem cell characteristics by regulating the target gene MYC,...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Comparison of cofilin‑1 and Twist‑1 protein expression in human non‑small cell lung cancer tissues. Oncol Rep. 2019 Jun 10;: Authors: Chang CY, Chang SL, Leu JD, Chang YC, Hsiao M, Lin LT, Lin HN, Lee YJ Abstract Metastasis is the primary cause of mortality in patients with non‑small cell lung cancer (NSCLC). Actin cytoskeletal reorganization is usually accompanied by the epithelial‑mesenchymal transition (EMT)‑induced invasion and metastasis of cancer cells. In the present study, expression levels of the actin‑associated protein cofilin‑1 and of the pivotal EMT molecule Twist‑1 were ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Conclusions: This study used gene expression data from a large cohort of patients to explore the molecular differences between lung ADC and SQCC.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The original article can be found online.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (EE) and drug loading (DL). DAPI staining and Flow cytometry techniques were employed to probe anticancer activities of the optimal formulations. The obtained results indicated th...
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Radium-223 dichloride (Xofigo, BAY 88-8223);   Drug: Pembrolizumab Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Virotherapy